Update on Diabetic Nephropathy: Core Curriculum 2018

American Journal of Kidney Diseases

Volumn 71, Issue 6, 2018, Pages 884-895

  Umanath, Kausik ^a   Lewis, Julia B ^b  

^a HENRY FORD HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

angiotensin receptor blocker (ARB); angiotensin converting enzyme inhibitor (ACEi); blood pressure; diabetes; Diabetic kidney disease; diabetic nephropathy; end stage kidney disease (ESKD); hemoglobin A1c (HbA1c); hypertension; RAS blockade; renin angiotensin system (RAS); review

Indexed keywords

ALISKIREN; AMLODIPINE; ANTIHYPERTENSIVE AGENT; CANAGLIFLOZIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMPAGLIFLOZIN; HEMOGLOBIN A1C; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE DURATION; END STAGE RENAL DISEASE; EPIDEMIOLOGICAL DATA; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; TREATMENT PLANNING; CASE REPORT; CHRONIC KIDNEY FAILURE; CURRICULUM; DISEASE EXACERBATION; DRUG EFFECT; FEMALE; HEMODIALYSIS; MORTALITY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CURRICULUM; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 85041598344     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2017.10.026     Document Type: Article

References (0)